Treatment of AIDS Vacuolar Myelopathy With Methionine

This study has been completed.
Sponsor:
Information provided by:
National Institute of Neurological Disorders and Stroke (NINDS)
ClinicalTrials.gov Identifier:
NCT00032695
First received: March 28, 2002
Last updated: May 12, 2006
Last verified: November 2005

March 28, 2002
May 12, 2006
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00032695 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Treatment of AIDS Vacuolar Myelopathy With Methionine
Not Provided

The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.

Myelopathy is usually a late complication of AIDS, and until recently its symptoms were rarely recognized, masked by the general state of disability or the presence of other neurological complications. With prolonged survival and improved quality of life of HIV-infected patients, myelopathy is increasingly becoming a common source of disability. The cause of AIDS-myelopathy is unknown, but it is probably an indirect effect of the long-term presence of the HIV virus in the nervous system rather than the result of a direct infection. The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.

Interventional
Phase 3
Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
  • Myelopathy
  • AIDS-Myelopathy
  • AIDS Vacuolar Myelopathy
Drug: methionine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
56
Not Provided
Not Provided

Between 18 and 80 years of age

Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00032695
R01NS35745
Not Provided
Not Provided
National Institute of Neurological Disorders and Stroke (NINDS)
Not Provided
Principal Investigator: Alessandro Di Rocco, MD
National Institute of Neurological Disorders and Stroke (NINDS)
November 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP